Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Lymphoid 1Breast 1

Conditions

Breast Neoplasms 102Neoplasm Metastasis 13Neoplasms 6Triple Negative Breast Neoplasms 5Breast Diseases 5Neoplasms by Site 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Unilateral Breast Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms, Male 2Breast Cancer Female 2Advanced Breast Cancer 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myeloproliferative Disorders 1

Interventions

pembrolizumab 2Cyclophosphamide 2Cisplatin 2sargramostim 1regorafenib 1fludarabine 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1abemaciclib 1Surgical Procedures, Operative 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Platinum 1Pemetrexed 1Paclitaxel 1Nivolumab 1Midazolam 1Microarray Analysis 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Interferon-gamma 1Interferon-alpha 1Immunoenzyme Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × abemaciclib × Breast × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡